Westshore Wealth LLC acquired a new position in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 21,948 shares of the biopharmaceutical company’s stock, valued at approximately $860,000. Pfizer makes up about 0.9% of Westshore Wealth LLC’s investment portfolio, making the stock its 16th biggest holding.
A number of other institutional investors also recently bought and sold shares of PFE. TFO TDC LLC purchased a new position in Pfizer in the 4th quarter valued at about $37,000. Wealthcare Capital Management LLC lifted its stake in Pfizer by 61.2% in the 4th quarter. Wealthcare Capital Management LLC now owns 1,069 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 406 shares in the last quarter. Stonebridge Financial Planning Group LLC purchased a new position in Pfizer in the 4th quarter valued at about $55,000. Cardinal Capital Management Inc. lifted its stake in Pfizer by 45.0% in the 4th quarter. Cardinal Capital Management Inc. now owns 1,450 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 450 shares in the last quarter. Finally, ICW Investment Advisors LLC purchased a new position in Pfizer in the 4th quarter valued at about $58,000. Institutional investors own 71.63% of the company’s stock.
Shares of NYSE:PFE traded up $0.20 on Tuesday, reaching $32.87. The company’s stock had a trading volume of 13,609,059 shares, compared to its average volume of 45,553,056. The stock’s 50-day moving average is $33.87 and its two-hundred day moving average is $36.87. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $44.56. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.88 and a quick ratio of 0.66. The stock has a market capitalization of $171.42 billion, a P/E ratio of 11.45, a PEG ratio of 2.49 and a beta of 0.69.
A number of research analysts have weighed in on the stock. Royal Bank of Canada decreased their target price on shares of Pfizer from $46.00 to $44.00 and set an “outperform” rating on the stock in a research note on Friday. Barclays began coverage on shares of Pfizer in a research note on Thursday, February 27th. They issued an “equal weight” rating and a $36.00 target price on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $37.00 price target on shares of Pfizer in a research report on Tuesday, January 28th. Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 target price on shares of Pfizer in a report on Thursday, March 19th. Finally, Standpoint Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, February 27th. Eight analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $41.19.
In other news, major shareholder Pfizer Inc acquired 312,500 shares of Pfizer stock in a transaction that occurred on Monday, March 16th. The shares were acquired at an average price of $16.00 per share, with a total value of $5,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Thursday, January 30th. The shares were purchased at an average cost of $37.15 per share, for a total transaction of $37,150.00. Following the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $148,600. The disclosure for this purchase can be found here. 0.08% of the stock is owned by corporate insiders.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: What is an Initial Coin Offering (ICO)?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.